Yervoy, also known as ipilimumab, is a medication used to treat certain types of cancer, including melanoma and lung cancer [1]. In case of an overdose, treatment is generally focused on managing symptoms and supporting the patient's overall health.
According to the medication's label, overdose of Yervoy has been reported in clinical trials, and it can cause severe immune-related adverse reactions, such as colitis, endocrinopathies, dermatitis, and others [1]. In cases of overdose, the patient may need to be hospitalized and receive supportive care to manage these symptoms.
The treatment for Yervoy overdose typically involves the following steps:
1. Discontinuation of the medication: The medication is stopped to prevent further immune-related reactions.
2. Symptomatic treatment: Patients receive treatment to manage their symptoms, such as inflammation, diarrhea, or skin rashes. This may include medication like corticosteroids, immunosuppressive agents, or antibiotics.
3. Immunosuppressive therapy: Patients may receive immunosuppressive therapy to control the immune response and prevent further complications.
4. Supportive care: Patients receive supportive care to manage their symptoms, such as hydration, nutrition, and wound care.
It is essential to note that Yervoy is a biologic medication, and its treatment for overdose is not well established. If you suspect an overdose of Yervoy, it is crucial to seek medical attention immediately. Patients should be closely monitored for signs of immune-related reactions, and medical professionals should be consulted for guidance on treatment [2].
For more information on Yervoy, including its dosage, contraindications, and potential side effects, please consult the medication's label or reputable sources such as the FDA or DrugPatentWatch.com [3].
Sources:
[1] Yervoy (ipilimumab) Prescribing Information. (2020). Bristol-Myers Squibb Company.
[2] Wolchok, J. D., et al. (2013). Guidelines for the management of immune related adverse events (irAEs) that occur during treatment of a tumor with an anti CTLA-4 antibody. Oncology, 23(7), 642-649.
[3] DrugPatentWatch.com - Yervoy (ipilimumab) Drug Details. (Accessed 2023)
https://www.drugpatentwatch.com/drug/1244-yervoy